Factors affecting participation in group intervention in patients after adjuvant treatment for early-study breast cancer

By Hamama-Raz Yaira   Perry Shlomit   Pat-Horenczyk Ruthy   Bar-Levav Ruth   Stemmer Solomon M.  

Acta Oncologica, Vol. 51, Iss. 2, 2012-02 ,pp. : 208-214

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

By van Wijk F.H.   Lhomme C.   Bolis G.   Scotto di Palumbo V.   Tumolo S.   Nooij M.   de Oliveira C.F.   Vermorken J.B.  

European Journal of Cancer, Vol. 39, Iss. 1, 2003-01 ,pp. : 78-85

Elsevier

Access to resources Recommend Favorite

Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group

By Aapro M.S.   van Wijk F.H.   van der Burg M.E.L.   ten Bokkel Huinink W.   Vergote I.   Guastalla J.P.   Rosso R.   Kobierska A.   Beex L.V.A.   Namer M.   Splinter T.E.W.   Vermorken J.B.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1141-1143

Elsevier

Access to resources Recommend Favorite

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

By Lhomme C.   Vermorken J.B.   Mickiewicz E.   Chevalier B.   Alvarez A.   Mendiola C.   Pawinski A.   Lentz M.A.   Pecorelli S.  

European Journal of Cancer, Vol. 36, Iss. 2, 2000-01 ,pp. : 194-199

Elsevier

Access to resources Recommend Favorite

Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases - a phase II study of the EORTC Lung Cancer Group (08965)

By Dziadziuszko R.   Ardizzoni A.   Postmus P.E.   Smit E.F.   Price A.   Debruyne C.   Legrand C.   Giaccone G.   on behalf of the EORTC Lung Cancer Group  

European Journal of Cancer, Vol. 39, Iss. 9, 2003-06 ,pp. : 1271-1276

Elsevier

Access to resources Recommend Favorite